Crucially, retatrutide is not yet licensed by the MHRA or EMA, and long-term cardiovascular outcomes data remain unavailable
Updated: March 9, 2026 On February 9, 2026, Novo Nordisk sued Hims & Hers Health
At Texas Regional Asthma, Allergy, and Immunology Center, your IV therapy is delivered in a calm, comfortable environmentwhile still being guided by medical expertise
The Institute for Clinical and Economic Review concluded that a fair value-based price would be \$5,000 to \$7,000 per year, well below the actual \$12,000+ list price patients face at Walgreens and every other retail counter